Document is current
Any future updates will be listed below
-
Authors
Glinos, Dafni A. https://orcid.org/0000-0001-5556-0222
Garborcauskas, Garrett https://orcid.org/0000-0003-0316-461X
Hoffman, Paul https://orcid.org/0000-0002-7693-8957
Ehsan, Nava
Jiang, Lihua
Gokden, Alper https://orcid.org/0000-0002-9659-7352
Dai, Xiaoguang
Aguet, François https://orcid.org/0000-0001-9414-300X
Brown, Kathleen L.
Garimella, Kiran
Bowers, Tera
Costello, Maura
Ardlie, Kristin
Jian, Ruiqi https://orcid.org/0000-0003-2406-5303
Tucker, Nathan R.
Ellinor, Patrick T. https://orcid.org/0000-0002-2067-0533
Harrington, Eoghan D.
Tang, Hua https://orcid.org/0000-0002-0177-8864
Snyder, Michael https://orcid.org/0000-0003-0784-7987
Juul, Sissel https://orcid.org/0000-0002-0315-4449
Mohammadi, Pejman
MacArthur, Daniel G. https://orcid.org/0000-0002-5771-2290
Lappalainen, Tuuli https://orcid.org/0000-0002-7746-8109
Cummings, Beryl B. https://orcid.org/0000-0001-6346-1646
- License Information
-
More Information
Article History
Received: 25 February 2021
Accepted: 28 June 2022
First Online: 3 August 2022
Competing interests
: D.A.G. is currently a fellow at Vertex Pharmaceuticals. X.D., E.D.H. and S.J. are employees of Oxford Nanopore Technologies and are shareholders and/or share option holders. F.A. has been an employee of Illumina, Inc., since 8 November 2021. P.T.E. has received sponsored research support from Bayer AG and IBM Health, and he has served on advisory boards or consulted for Bayer AG, MyoKardia and Novartis; none of these activities are related to the work presented here. D.G.M. is a founder with equity in Goldfinch Bio, a paid advisor to GSK, Insitro, Third Rock Ventures and Foresite Labs, and has received research support from AbbVie, Astellas, Biogen, BioMarin, Eisai, Merck, Pfizer and Sanofi-Genzyme; none of these activities are related to the work presented here. B.C. is currently employed at Third Rock Ventures. The other authors declare no competing interests.
